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Abstract
Background: Drug resistance is a major concern in cancer therapy. Here, we investigate the
clinical potential of the second mitochondria-derived activator of caspase (Smac/DIABLO) in
enhancing the apoptosis-inducing potential of commonly used anticancer drugs (paclitaxel,
doxorubicin, etoposide, tamoxifen), irradiation and TRAIL in breast carcinoma.
Methods: Breast cancer cells were overexpressed with Smac/DIABLO gene (full-length or Δ55
Smac/DIABLO) or treated with Smac/DIABLO peptide to enhance the apoptosis-inducing potential
of chemotherapeutic drugs and irradiation, and sensitize TRAIL-resistant cells. Cell viability and
apoptosis were measured by XTT assay and DAPI staining, respectively. Protein-protein
interaction was determined by immunoprecipitation followed by the Western blot analysis.
Results: Overexpression of Smac/DIABLO gene (full-length or Δ55 Smac/DIABLO) or treatment
with Smac/DIABLO peptide enhances apoptosis induced by paclitaxel, doxorubicin, etoposide,
tamoxifen, and irradiation in breast cancer cells. Overexpression of Smac/DIABLO resulted in an
increased interaction of Smac/DIABLO with IAPs, which correlated with an increase in caspase-3
activity and apoptosis. Furthermore, Smac/DIABLO sensitized TRAIL-resistant breast cancer cell
lines to undergo apoptosis through caspase-3 activation. These data suggest that apoptotic events
down-stream of mitochondria were intact in TRAIL-resistant cells since ectopic expression of
Smac/DIABLO or pretreatment of cells with Smac/DIABLO peptide completely restored TRAIL
sensitivity.
Conclusion: The ability of Smac/DIABLO agonists to enhance the apoptosis-inducing potential of
chemotherapeutic drugs and irradiation, and sensitize TRAIL-resistant tumor cells suggests that
Smac/DIABLO may induce fundamental alterations in cell signaling pathways. Thus, Smac/DIABLO
agonists can be used as promising new candidates for cancer treatment by potentiating cytotoxic
therapies.
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Background
The family of cysteine proteases known as caspases are the
key components of apoptosis or programmed cell death
[1]. TRAIL (TNF-related apoptosis-inducing ligand), a
member of TNF family, uses caspase activation as a sign-
aling mechanism leading to apoptosis via two distinct
pathways, involving either ligation of death receptors at
the cell surface in recruitment of certain procaspases or
through the mitochondrial pathway with release of apop-
togenic factors such as cytochrome c and Smac/DIABLO
into the cytosol along with several other factors such as
endonuclease G, apoptotic inducing factor (AIF) and
Omi/Htr A2, in parallel with the profound loss of mito-
chondrial membrane potential [2]. A cross talk exists
between apoptotic pathways mediated by cell death
receptors and mitochondria through the caspase 8-
dependent Bid cleavage (a Bcl-2 family protein) [3]. The
activation of initiator caspases such as caspase 8 and cas-
pase 9 is thought to irreversibly trigger the caspase cas-
cade, necessitating that caspase activation is tightly
regulated by layered control mechanism.
Several endogenous antagonists of caspase activation
pathway which lead to dysregulation of their expression
or function in cancer cells have been discovered, such
alterations include an impaired ability of the cancer cell to
undergo apoptosis. The cellular proteins shown to regu-
late caspase activation and activity are the IAP's (inhibi-
tion of apoptosis protein) including cIAP-1, cIAP-2, XIAP
and survivin [4]. These proteins are reported to block
death receptors and mitochondrial mediated apoptotic
pathways by directly inhibiting initiator and effector cas-
pases. Mitochondrial proapoptotic protein Smac/DIABLO
is shown to potentiate apoptosis by counteracting the anti
apoptotic function of the IAP's. All IAP's contain at least 1,
while some contain 3 BIR (baculovirus IAP repeat)
domains [4]. XIAP through BIR domains mediate both its
inhibiting activity on caspases and the protein-protein
interaction with Smac/DIABLO. During apoptosis, the
mitochondrial Smac/DIABLO is released into the cytosol
and binds to XIAP by which it antagonizes XIAP interac-
tion with caspase 9, thereby promoting the activity of cas-
pase 9, followed by caspase 3 and apoptosis. The N-
terminal peptide (AVPIAQK) of Smac/DIABLO can bind
across in a surface groove of BIR 3 of XIAP in a mutually
exclusive manner with caspase 9. We have recently dem-
onstrated that mitochondrial events are required for
TRAIL-induced apoptosis [5]. Ectopic overexpression of
Smac/DIABLO completely restored TRAIL sensitivity by
negative regulation of caspase cascade through XIAP [5].
Expression of a cytosolic active form of Smac/DIABLO or
cell permeable Smac/DIABLO peptide bypassed the Bcl-2
block, which prevented the release of Smac/DIABLO from
mitochondria.
The objective of the paper is to examine whether Smac/
DIABLO enhances the apoptosis-inducing potential of
chemotherapeutic drugs (paclitaxel, tamoxifen and doxo-
rubicin) and irradiation, and sensitizes TRAIL-resistant
breast cancer cells. The results demonstrate that Smac/
DIABLO gene or cell permeable Smac/DIABLO peptide
enhances the apoptosis-inducing potential of chemother-
apeutic drugs and irradiation, and sensitizes TRAIL-resist-
ant breast cancer cells to apoptosis. Thus, Smac/DIABLO
gene or Smac/DIABLO peptide can be used to enhance the
effectiveness of commonly used anticancer drugs, irradia-
tion and TRAIL in breast cancer.
Results
Smac/DIABLO peptide enhances antiproliferative and 
proapoptotic effects of TRAIL in MCF-7 cells, and 
sensitizes TRAIL-resistant MDA-MB-453 and MDA-MB-
468 cells
We have taken two approaches to examine the effects of
Smac/DIABLO in breast cancer cells. In first approach, the
Smac/DIABLO (Smac/DIABLO N7, H-AVPIAQK-OH)
and control peptides were used. In the second approach,
cells were transfected with plasmids expressing full length
Smac/DIABLO (pCDNA3-Smac/DIABLO-flag), Δ55
Smac/DIABLO (pCDNA3-Δ55 Smac/DIABLO-flag) or neo
(pCDNA3-neo-flag). The NH2 terminus of Smac/DIABLO
(55 residues containing the MTSs) is removed by proteol-
ysis to generate the mature and functional form (contain-
ing 184 amino acid) of the molecule during
mitochondrial import. The goal was to increase the
amount of Smac in the cytosol either by pharmacological
or genetic method.
We first measured the effects of Smac/DIABLO on antipro-
liferative and proapoptotic activity of TRAIL in MCF-7
cells (Fig. 1A). Control Smac/DIABLO peptide (Smac/
DIABLO C) had no effect on cell viability and apoptosis.
Smac/DIABLO peptide (Smac/DIABLO P) slightly inhib-
ited cell viability and induced apoptosis. TRAIL induced
apoptosis in MCF-7 cells pretreated with or without Smac/
DIABLO control peptide. The levels of apoptosis by TRAIL
in MCF-7 cells pretreated with Smac/DIABLO control
peptide was higher than the apoptosis noted in TRAIL-
untreated control group. Treatment of MCF-7 cells with
Smac/DIABLO peptide increased the effects of TRAIL on
cell viability and apoptosis (Fig. 1A). Overexpression of
full-length Smac/DIABLO or Δ55 Smac/DIABLO
enhanced the antiproliferative effects of TRAIL in MCF-7
cells (Fig. 1B).
We next examined whether Smac/DIABLO peptide can
sensitize TRAIL-resistant MDA-MB-453 and MDA-MB-
468 breast cancer cells. Smac/DIABLO control peptide
had no effect on cell viability (Fig. 1C and 1D). Smac/
DIABLO peptide (50 and 100 μM) inhibited cell viabilityMolecular Cancer 2008, 7:60 http://www.molecular-cancer.com/content/7/1/60
Page 3 of 10
(page number not for citation purposes)
in MDA-MB-453 and MDA-MB-468 cells. Smac/DIABLO
peptide (25–100 μM) sensitized TRAIL-resistant MDA-
MB-453 and MDA-MB-468 breast cancer cells in a dose-
dependent manner. These data suggest that Smac/DIA-
BLO peptide can be used to sensitize TRAIL-resistant
breast cancer cells.
Interactive effects of Smac/DIABLO with 
chemotherapeutic drugs, irradiation and TRAIL on cell 
viability, apoptosis and colony formation in breast cancer 
cells
In addition to TRAIL, we have also used commonly used
anticancer drugs (tamoxifen, doxorubicin and paclitaxel)
Interactive effects of Smac/DIABLO with TRAIL on cell viability and apoptosis Figure 1
Interactive effects of Smac/DIABLO with TRAIL on cell viability and apoptosis. (A), MCF-7 cells were pretreated 
with either Smac/DIABLO control peptide (25 μM) or Smac/DIABLO N7 peptide (25 μM) for 12 h, followed by treatment with 
TRAIL (75 nM) for 36 h. Cell viability and apoptosis were measured by XTT assay and DAPI staining, respectively. Data repre-
sent mean ± SE. * = significantly different from the respective control at P < 0.05. (B), MCF-7 cells were transiently transfected 
with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with TRAIL (75 nM) for 36 h. Cell 
viability was measured by XTT assay. Data represent mean ± SE. * = significantly different from the respective control at P < 
0.05. Smac C = Smac control peptide, Smac P = Smac N7 peptide. (C), MDA-MB-453 cells were pretreated with various doses 
of either Smac/DIABLO control peptide (0–100 μM) or Smac/DIABLO N-7 peptide (0–100 μM) for 12 h, followed by treat-
ment with TRAIL (75 nM) for 36 h. Cell viability was measured by XTT assay. Data represent mean ± SE. *, # = significantly dif-
ferent from the respective control at P < 0.05. (D), MDA-MB-468 cells were pretreated with various doses of either Smac/
DIABLO control peptide (0–100 μM) or Smac/DIABLO N-7 peptide (0–100 μM) for 12 h, followed by treatment with TRAIL 
(75 nM) for 36 h. Cell viability was measured by XTT assay. Data represent mean ± SE. *, # = significantly different from the 
respective control at P < 0.05.
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and irradiation as therapeutic agents. Overexpression of
full-length Smac/DIABLO (Smac/DIABLO FL) or mature
form of Smac/DIABLO (Smac/DIABLO Δ55) enhanced
the inhibitory effects of tamoxifen, doxorubicin, and pacl-
itaxel on cell viability, and sensitized MDA-MB-453 and
MDA-MB-468 cells to TRAIL (Fig. 2A and 2B). Further-
more, overexpression of Smac/DIABLO FL or Smac/DIA-
BLO Δ55 enhanced paclitaxel-, doxorubicin-, etoposide,
tamoxifen-, and irradiation-induced apoptosis, and sensi-
tized MDA-MB-453 and MDA-MB-468 cells to TRAIL (Fig.
2C and 2D). Similarly, overexpression of Smac/DIABLO
FL or Smac/DIABLO Δ55 enhanced paclitaxel-, doxoru-
bicin-, etoposide-, and tamoxifen-induced apoptosis in
MCF-7 cells (data not shown). Smac/DIABLO Δ55 was
more effective in inhibiting cell viability and promoting
apoptosis compared to full length Smac/DIABLO.
Since overexpression of Smac/DIABLO enhanced the
apoptosis-inducing potential of chemotherapeutic drugs
and irradiation, and sensitized TRAIL-resistant cells, we
next sought to examine the interactive effects of Smac/
DIABLO peptide with these agents (Fig. 3A and 3B). Smac
control peptide (Smac C) or TRAIL alone had no effect on
apoptosis. Paclitaxel, doxorubicin, etoposide, tamoxifen
Effects of Smac/DIABLO with chemotherapeutic drugs or TRAIL on cell viability Figure 2
Effects of Smac/DIABLO with chemotherapeutic drugs or TRAIL on cell viability. (A), MDA-MB-453 cells were 
transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with 
tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL (75 nM) for 36 h. Cell viability was measured by XTT 
assay. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05. (B), MDA-MB-468 
cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated 
with tamoxifen (100 nM), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL (75 nM) for 36 h. Cell viability was measured by 
XTT assay. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05. (C), MDA-MB-
453 cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and 
treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), tamoxifen (100 nm), irradiation (5 Gy) or TRAIL 
(75 nM) for 36 h. Apoptosis was measured by DAPI staining. Data represent mean ± SE. *, #, & = significantly different from 
the respective control at P < 0.05. (D), MDA-MB-468 cells were transiently transfected with plasmids expressing Smac/DIA-
BLO full length, Smac Δ55 or neo for 24 h, and treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), 
tamoxifen (100 nm), irradiation (5 Gy) or TRAIL (75 nM) for 36 h. Apoptosis was measured by DAPI staining. Data represent 
mean ± SE. *, #, & = significantly different from the respective control at P < 0.05.
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and irradiation induced apoptosis in both MDA-MB-453
and MDA-MB-468 cells. Interestingly, Smac/DIABLO pep-
tide enhanced paclitaxel-, doxorubicin-, etoposide-,
tamoxifen-, and irradiation-induced apoptosis, and sensi-
tized TRAIL-resistant MDA-MB-453 and MDA-MB-468
cells to TRAIL. Similarly, Smac/DIABLO peptide enhanced
paclitaxel-, doxorubicin-, etoposide-, and tamoxifen-
induced apoptosis in MCF-7 cells (data not shown).
Since Smac/DIABLO peptide enhanced the apoptosis-
inducing potential of anticancer drugs, and sensitized
TRAIL-resistant breast cancer cells, we sought to examine
whether they have similar effects on colony formation
(Fig. 3C and 3D). Tamoxifen, doxorubicin and paclitaxel
inhibited colony formation in both MDA-MD-453 and
MDA-MB-468 cells. In contrast, TRAIL or control peptide
had no effect on colony formation. Similar to apoptosis,
Smac/DIABLO peptide enhanced the inhibitory effects of
anticancer drugs on colony formation, and sensitized
TRAIL-resistant cells. These data suggest that Smac/DIA-
BLO can be used to enhance the apoptosis-inducing
potential of tamoxifen, doxorubicin and paclitaxel, and
sensitize TRAIL-resistant breast cancer cells.
Smac/DIABLO enhances drug-induced apoptosis and 
sensitizes TRAIL-resistant cells through caspase-3 
activation and PARP cleavage
Caspase activation appears to be common pathway in
apoptosis induced by stress stimuli in many systems [6-8].
Since Smac/DIABLO augments drug-induced apoptosis
and sensitizes TRAIL-resistant cells, we sought to examine
the mechanism of this interaction by measuring caspase-
3 activation. Tamoxifen, doxorubicin and paclitaxel
induced caspase-3 activity in both MDA-MD-453 and
Interactive effects of Smac/DIABLO peptide with chemotherapeutic drugs or TRAIL on apoptosis and colony formation Figure 3
Interactive effects of Smac/DIABLO peptide with chemotherapeutic drugs or TRAIL on apoptosis and colony 
formation. (A), MDA-MB-453 cells were pretreated with either Smac control peptide (25 μM) or Smac N-7 peptide (25 μM) 
for 12 h, and treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), tamoxifen (100 nm), irradiation (5 
Gy) or TRAIL (75 nM) for 36 h. Apoptosis was measured by DAPI staining. Data represent mean ± SE. *, #, & = significantly dif-
ferent from the respective control at P < 0.05. (B), MDA-MB-468 cells were pretreated with either Smac control peptide (25 
μM) or Smac N-7 peptide (25 μM) for 12 h, and treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), 
tamoxifen (100 nm), irradiation (5 Gy) or TRAIL (75 nM) for 36 h. Data represent mean ± SE. *, #, & = significantly different 
from the respective control at P < 0.05. (C), MDA-MB-453 cells were pretreated with either Smac control peptide (25 μM) or 
Smac N-7 peptide (25 μM) for 12 h, and treated with tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL 
(75 nM) for 21 days. No. of colonies were determined by soft agar assay. Data represent mean ± SE. *, #, & = significantly dif-
ferent from the respective control at P < 0.05. (D), MDA-MB-468 cells were pretreated with either Smac control peptide (25 
μM) or Smac N-7 peptide (25 μM) for 12 h, and treated with tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) 
or TRAIL (75 nM) for 21 days. No. of colonies were determined by soft agar assay. Data represent mean ± SE. *, #, & = signif-
icantly different from the respective control at P < 0.05. represent mean ± SE.
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MDA-MB-468 cells (Fig. 4A). In contrast, TRAIL or control
peptide alone had no effect on caspase-3 activity. Treat-
ment of cells with Smac/DIABLO peptide further
enhanced drug-induced caspase-3 activation. Further-
more, the combination of Smac/DIABLO and TRAIL
resulted in caspase-3 activity in TRAIL-resistant breast can-
cer cells. Similar effects were obtained with full-length
Smac/DIABLO (Smac/DIABLO FL) and Smac/DIABLO
Δ55 in both MDA-MD-453 and MDA-MB-468 cells,
although Smac/DIABLO Δ55 was more potent than Smac/
DIABLO FL (Fig. 4B). These data suggest that Smac/DIA-
BLO enhances the apoptosis-inducing potential of anti-
cancer drugs and sensitizes TRAIL-resistant cells through
caspase-3 activation.
Activation of caspase results in cleavage of several sub-
strates such as poly ADP ribose polymerase (PARP)
enzyme that can be used as a marker of apoptosis [9,10].
Interactive effects of Smac/DIABLO peptide with chemotherapeutic drugs or TRAIL on caspase-3 activity and PARP cleavage Figure 4
Interactive effects of Smac/DIABLO peptide with chemotherapeutic drugs or TRAIL on caspase-3 activity and 
PARP cleavage. (A), MDA-MB-453 or MDA-MB-468 cells were pretreated with either Smac control peptide (25 μM) or 
Smac N-7 peptide (25 μM) for 12 h, and treated with tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL 
(75 nM) for 24 h. Caspase-3 activity was measured as per the manufacturer's instructions (Calbiochem). Data represent mean 
± SE. *, #, & = significantly different from the respective control at P < 0.05. (B), MDA-MB-453 or MDA-MB-468 cells were 
transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with 
tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL (75 nM) for 24 h. Caspase-3 activity was measured as 
per the manufacturer's instructions (Calbiochem). Data represent mean ± SE. *, #, & = significantly different from the respec-
tive control at P < 0.05. (C), MDA-MB-468 cells were transiently transfected with plasmids expressing Smac/DIABLO full 
length or neo for 24 h, and treated with doxorubicin (100 nM), TRAIL (75 nM), tamoxifen (100 nm) or paclitaxel (100 nM) for 
24 h. Western blot analysis was performed to measure the cleavage of PARP. Anti-β-actin antibody was used as a loading con-
trol.
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MDA-MB-468 cells were transiently transfected with plas-
mids expressing Smac/DIABLO (MDA-MB-468/Smac/
DIABLO) or neo (MDA-MB-468/neo), and treated with or
without doxorubicin, TRAIL, tamoxifen or paclitaxel for
48 h, and cleavage of PARP was determined by the West-
ern blot analysis (Fig. 4C). The antibody recognizes only
the cleavage product of PARP. Chemotherapeutic drugs
significantly induced PARP cleavage. Overexpression of
Smac/DIABLO resulted in enhanced cleavage of PARP in
MDA-MB-468/Smac/DIABLO cells treated with doxoru-
bicin, TRAIL, tamoxifen or paclitaxel. These data suggest
that Smac/DIABLO enhances the apoptosis-inducing
potential of anticancer drugs and sensitizes TRAIL-resist-
ant cells through PARP cleavage.
Interaction of Smac/DIABLO with IAPs
The apoptotic death of cells requires proteolytic activation
of caspases which are synthesized as latent proenzymes
[6,7]. Once activated, caspases cleave a wide range of mol-
ecules (e.g. PARP) that eventually result in the dismantle-
ment of cells [11,12]. Active caspases can be specifically
inhibited by inhibitors of apoptosis (IAP). IAP antago-
nists (Smac/DIABLO, Omi/HtrA2 and GSPT1/eRF3) com-
pete with caspases for IAP-binding and consequently
relieve caspases and promote cell death. Since Smac/DIA-
BLO augments drug-induced apoptosis, and sensitizes
TRAIL-resistant cells, we sought to examine the interac-
tions of Smac/DIABLO with cIAP1, cIAP2 and XIAP.
MDA-MB-468/Neo and MDA-MB-468/Smac/DIABLO
cells were treated with doxorubicin, paclitaxel, tamaxifen
or TRAIL for 24 h (Fig. 5). Cell lysates were immunopre-
cipitated with anti-Smac/DIABLO antibody, and immu-
noblotted with anti-cIAP1, cIAP2 or XIAP antibodies.
Treatment of MDA-MB-468/neo with chemotherapeutic
drugs enhanced the interaction of Smac/DIABLO with
IAPs. Interactions of Smac/DIABLO and IAPs were further
increased when cells were transfected with Smac/DIABLO.
These data suggest that the ability of Smac/DIABLO to
enhance drug-induced apoptosis is due to sequestration
of IAPs, which, in turn, causes caspase activation and
apoptosis.
Discussion
Our studies provide a rational for the development of
combined treatment regimens when Smac/DIABLO ago-
nists enhance the apoptotic response of commonly used
chemotherapeutic drugs, irradiation or TRAIL for the
treatment of breast cancer. We have shown that Smac/
DIABLO enhances the apoptosis-inducing potential of
chemotherapeutic drugs (tamoxifen, doxorubicin, or
paclitaxel), irradiation and sensitized TRAIL-resistant
breast cancer cells in vitro by activating caspases-3.
Although TRAIL was ineffective alone, Smac/DIABLO sen-
sitizes TRAIL-resistant MDA-MB-468 breast cancer cells.
We have previously documented the role of mitochondria
in TRAIL-induced apoptosis [10]. Caspase-8 activation by
TRAIL is necessary but not sufficient to induce apoptosis.
Crosstalk between the death-receptor and mitochondrial
pathways is mediated by caspase-8 cleavage of Bid to tBid
[10,13-15]. tBid activates proapoptotic members Bak and
Bax to release cytochrome c and Smac/DIABLO from
mitochondria [5,16]. We have recently shown that the
release of cytochrome c and Smac/DIABLO is differen-
tially regulated by Bax and Bak [5]. In epithelial cells,
mitochondria amplify the apoptotic signals leading to
activation of caspase-9 followed by caspase-3. The syner-
gistic effects of chemotherapeutic drugs (paclitaxel, vinc-
ristine, vinblastine, etoposide, camptothecin and
doxorubicin) or irradiation with TRAIL on apoptosis
occur through activation of downstream caspase-3, which
can be activated by both mitochondria-dependent and -
independent pathways [17]. Activation of caspase cleaves
several substrates leading to apoptotic cell death.
There are many factors contributing to the resistance to
TRAIL. However, it is not clear whether the mechanism of
resistance to TRAIL is constitutive or inductive. Several
endogenous factors of TRAIL resistance have been pro-
posed; which include (i) low expression of death recep-
tors, (ii) overexpression of cFLIP, proapoptotic members
of Bcl-2 family (e.g. Bcl-2 and Bcl-XL) and IAPs, (iii) muta-
Interaction of Smac/DIABLO with IAPs Figure 5
Interaction of Smac/DIABLO with IAPs. MDA-MB-468 
cells were transiently transfected with plasmids expressing 
Smac/DIABLO full length (MDA-MB-468/Smac) or neo 
(MDA-MB-468/neo) gene for 24 h, and treated with doxoru-
bicin (100 nM), paclitaxel (100 nM), tamoxifen (100 nm) or 
TRAIL (75 nM) for 24 h. Cells were harvested, and immuno-
precipitated with anti-Smac antibody. Immunoprecipitated 
complexes were subjected to SDS-PAGE and immunoblotted 
with anti-cIAP1, anti-cIAP2 or anti-XIAP antibody. Anti-β-
actin antibody was used as a control in whole cell lysate.
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tions in Bax or/or Bak gene, and (iv) defects in the release
in the mitochondrial proteins. Furthermore, the inability
of TRAIL to down regulate anti-apoptotic genes and up-
regulate pro-apoptotic genes may also contribute to TRAIL
sensitivity/resistance. In the present study, we have shown
that the exogenous Smac/DIABLO can enhance the apop-
totic response of chemotherapeutic drugs and irradiation,
and sensitizes TRAIL-resistant cells. In addition, the inter-
action of Smac/DIABLO with chemotherapeutic drugs or
TRAIL on apoptosis occur through enhance binding of
IAPs with Smac/DIABLO resulting in an increased activa-
tion of caspase-3.
The N-terminus of Smac/DIABLO (55 residues containing
the mitochondrial targeting sequences, MTS) is removed
by proteolysis to generate the mature and functional form
(containing 184 amino acids) of the molecule during
mitochondrial import [18,19]. Ectopic overexpression of
Smac/DIABLO potentiates epothilone B derivative (BMS)-
induced apoptosis [20]. Furthermore, Smac/DIABLO ago-
nists sensitized various tumor cells in vitro and in vivo for
apoptosis induced by death-receptor ligation or cytotoxic
drugs [21-23]. Most importantly, Smac/DIABLO peptides
strongly enhanced the antitumor activity of TRAIL in an
intracranial malignant glioma xenograft model in vivo
[21]. Complete eradication of established tumors and sur-
vival of mice was only achieved upon combined treat-
ment with Smac/DIABLO peptides and TRAIL without
detectable toxicity to normal brain tissue. Thus, Smac/
DIABLO agonists are promising candidates for cancer
therapy by potentiating cytotoxic therapies.
The toxicity of FasL and TNF to non-transformed cells pre-
cludes their clinical use [24]. TRAIL, however, causes only
minimal toxic effects in normal hepatocytes [25], and the
toxic effects can be overcome by simultaneous exposure to
the caspase inhibitor, Z-LEHD-FMK [26]. Soluble and
native TRAIL has been shown to have no toxicity in rat,
mice and nonhuman primates [27,28], suggesting its use
as a potential anticancer agent [29]. We have previously
shown that most breast cancer cell lines were resistant to
TRAIL, and chemotherapeutic drugs (paclitaxel, vincris-
tine, vinblastine, etoposide and camptothecin) or irradia-
tion sensitized TRAIL-resistant cells to undergo apoptosis
through upregulation of death receptor DR4 and/or DR5
and activation of caspase-3 [12,30]. In the present study,
we have demonstrated that TRAIL-resistant breast cancer
cell lines can be sensitized by Smac/DIABLO (peptide or
gene).
Conclusion
We have developed a novel strategy of combining Smac/
DIABLO agonists with chemotherapeutic drugs, irradia-
tion or TRAIL for the treatment of human breast cancer.
Specifically, Smac/DIABLO increases the apoptosis-induc-
ing potential of chemotherapeutic drugs (paclitaxel, dox-
orubicin and tamoxifen) and irradiation, and sensitizes
TRAIL-resistant cells to undergo apoptosis through
enhanced binding of Smac/DIABLO with IAPs and an
increased in caspases-3 activity. Furthermore, our studies
provide a foundation for the development of combined
treatment regimens that would enhance the apoptotic
response in both TRAIL-sensitive and TRAIL-resistant
cells. Thus, it may be feasible to deliver Smac/DIABLO
either through gene therapy or through small molecules/
peptides to enhance the clinical applications of com-
monly used anticancer drugs, irradiation and TRAIL.
Methods
Reagents
Anti Smac/DIABLO, cIAP1, cIAP2, XIAP and β-actin anti-
bodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Caspase-3 assay kit and antibody
against β-actin were purchase from Oncogene Research
(Cambridge, MA). Antibodies against caspase-3 and poly
ADP ribose polymerase (PARP) were purchased from Bio-
source International, Inc. (Camarillo, CA). TRAIL was syn-
thesized as described earlier [31]. Enhanced
chemiluminescence (ECL) western blot detection reagents
were from Amersham Life Sciences Inc. (Arlington
Heights, IL). Lipofectamine reagent was from Invitrogen
life technologies (Carlsbad, CA).
Cell culture and transfection
Breast cancer MCF-7, MDA-MB-468 and MDA-MB-453
cells were obtained from the American Type Culture Col-
lection (Manassas, VA). Cells were grown in RPMI 1640
supplemented with D-glucose, HEPES buffer, 2 mM L-
glutamine, 1% penicillin-streptomycin mixture, and 10%
fetal bovine serum. Cells were grown in tissue culture
dishes at 37°C with 5% CO2. Cells were transfected with
pCDNA3neo-Smac/DIABLO, pCDNA3neo-Δ55 Smac/
DIABLO or pCDNA3neo plasmids as we described else-
where [5].
Smac/DIABLO peptide
The AVPIAQK sequence (located at the amino terminus
after MTS) of Smac/DIABLO is absolutely required for its
ability to interact with the baculovirus IAP repeat (BIR3)
of XIAP and to promote cytochrome c dependent caspase
activation. Smac/DIABLO control peptide (H-MKSDFYF-
P-RQIKIWFQNRRMKWKK-OH) and Smac/DIABLO-N7
(H-AVPIAQK-P-RQIKIWFQNRRMKWKK-OH) peptides
were used at doses ranging from 25 to 100 μM. The Smac/
DIABLO-N7 peptide is modified to be cell permeable by
linking the lysine carboxyl terminal to the arginine of
Antennapedia homeodomain 16-mer peptide (underlined)
via a proline linker.Molecular Cancer 2008, 7:60 http://www.molecular-cancer.com/content/7/1/60
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XTT Assay
XTT assays were performed as we described before [32]. In
brief, cells (1 × 104 in 200 μl culture medium per well)
were seeded in 96-well plates (flat bottom), and treated
with drugs in the presence or absence of TRAIL. Plates
were incubated for various time points at 37°C with 5%
CO2. Before the end of the experiment, 50 μl XTT (sodium
3' [1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-
methoxy-6-nitro) benzene sulfonic acid hydrate) labeling
mixture (final concentration, 125 μM sodium XTT and 25
μM PMS) per well was added and plates were incubated
for additional 4 h at 37°C and 5% CO2. The spectropho-
tometric absorbance of the sample was measured using a
microtitre plate (ELISA) reader. The wavelength to meas-
ure absorbance of the formazan product was 450 nm, and
the reference wavelength was 650 nm.
Western Blot Analysis
Cells were lysed in a buffer containing 10 mM Tris-HCl
(pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1%
SDS, 1 mM sodium orthovanadate, and a mixture of pro-
tease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1
μg/ml pepstatin A, 2 μg/ml aprotinin). Lysates were soni-
cated for 10 s, centrifuged for 20 min at 10,000 × g and
stored at -70°C. Equal amounts of crude proteins were
run on 10% SDS-PAGE gels and electrophoretically trans-
ferred to nitrocellulose. Nitrocellulose blots were blocked
with 6% nonfat dry milk in TBS buffer (20 mM Tris-HCl
(pH 7.4), 500 mM NaCl, and 0.01% Tween 20) for 1 hr,
washed in TBST three times (10, 5 and 5 min each) and
incubated with primary antibody in TBS containing 1%
bovine serum albumin overnight at 4°C. Blots were
washed three times (10, 5, 5 min each). Immunoreactivity
was detected by sequential incubation with horseradish
peroxidase-conjugated secondary antibody and ECL rea-
gents.
Measurement of Apoptosis
Apoptosis was measured by DAPI staining as we described
earlier [5].
Statistical Analyses
For each studied variable, mean and SEM were calculated.
Differences between groups were analyzed by one or two
way ANOVA (P <0.05).
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